Gossamer Bio Inc.

AI Score

0

Unlock

0.86
-0.06 (-6.82%)
At close: Jan 14, 2025, 3:59 PM
0.92
6.80%
Pre-market Jan 15, 2025, 06:03 AM EST
undefined%
Bid 0.86
Market Cap 194.56M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.25
PE Ratio (ttm) -3.43
Forward PE n/a
Analyst Buy
Ask 0.87
Volume 744,660
Avg. Volume (20D) 1,372,075
Open 0.93
Previous Close 0.92
Day's Range 0.82 - 0.94
52-Week Range 0.50 - 1.60
Beta undefined

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hy...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2019
Employees 135
Stock Exchange NASDAQ
Ticker Symbol GOSS

Analyst Forecast

According to 5 analyst ratings, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 948.22% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Gossamer Bio Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of $7.02M, reflecting a n/a YoY growth and earnings per share of -0.17, making a -19.05% decrease YoY.
6 months ago · Source
+22.26%
Gossamer Bio shares are trading higher after Oppen... Unlock content with Pro Subscription
7 months ago · Source
+0.02%
Gossamer Bio shares are trading higher after competitor Aerovate Therapeutics reported topline results from the Phase 2b portion of IMPAHCT trial of AV-101 for pulmonary arterial hypertension.